This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will develop and evaluate a universal overdose prevention intervention delivered through primary care settings to reduce youth overdose risk. The $2,467,574 award, effective September 30, 2024 through August 31, 2026, will fund a pilot study and subsequent larger randomized controlled trial to assess the intervention's impact on increasing youth awareness...
This $721,217 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to increase naloxone availability and use in high-risk settings, using public libraries as a novel approach to promote overdose reversal. The primary objectives are to: 1) understand institutional barriers and facilitators of naloxone uptake in public libraries; 2) establish a cohort to monitor naloxone uptake and overdose outcomes in...
This $424,545 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a national survey on naloxone use and access. The project, conducted by The RAND Corporation, aims to gather timely evidence on naloxone carrying rates, purchasing behavior, and barriers to obtaining naloxone in the United States. The survey data will be collected from a nationally representative sample as well as individuals self-reporting...
The federal Project Grant award R01DA062152 was issued by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). This $1,499,606 award, effective September 30, 2024 through July 31, 2029, will fund research by Dartmouth-Hitchcock Clinic to characterize the health outcomes of children born to individuals with opioid use disorder (OUD) from birth to 5 years of age. The project aims to identify disparities in outcomes based on race,...
This Project Grant award of $598,312 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support the integration and assessment of Addinex Technologies, Inc.'s closed-loop medication management system for opioid pain management in ambulatory patients with extremity fractures being discharged from the emergency department. The primary objectives are to: 1) adapt and enhance the Addinex system to align with hospital pharmacy...
This $2,316,128 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to design tailored harm reduction strategies to address the overdose crisis across six distinct jurisdictions. The project, titled "REVERSING OVERDOSE EPIDEMICS THROUGH SIMULATION, COLLABORATION, AND UNIFIED EFFORTS (RESCUE)", will collaborate with health departments and community partners to assess the effectiveness,...
This Project Grant award of $157,684 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to understand inequities in harm reduction services provided to persons with opioid use disorder in hospital settings. The key products and services to be delivered under this award include: Developing and validating a natural language processing (NLP) system to identify patterns of harm reduction language and other relevant data in...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,607,146 to NDRI-USA Inc., a non-profit research organization, for the project "TOGETHER AGAINST OVERDOSE: COMMUNITY DEVELOPED TECHNOLOGY TO ENCOURAGE DRUG CHECKING, DISTRIBUTION OF HARM REDUCTION SUPPLIES, AND LINKAGE TO SERVICES." The project aims to develop technology-based interventions in English and Spanish to increase...
This $2,542,500 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support the development of novel econometric research methods to integrate real-world evidence (RWE) data into the analysis of inconclusive randomized controlled trials (RCTs) for opioid use disorder (OUD) treatments. The project aims to create a unified framework for using RWE to supplement RCT findings, particularly for vulnerable...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will test a bundled intervention to increase treatment uptake for patients with opioid use disorder (OUD) after emergency department (ED) discharge. The $844,475 award, spanning September 2024 to August 2026, will first enroll 30 patients in a feasibility study (R61 phase) to assess the acceptability of the intervention. This intervention involves daily...
This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) aims to evaluate a pharmacist-integrated model of opioid use disorder treatment to increase naloxone co-prescribing in primary care. The $193,336 grant awarded to Trustees of Dartmouth College will fund a research project with the following objectives:
Describe federal, state, and clinic-level policies and current interventions impacting naloxone co-prescribing at four primary care sites in four states.
Investigate care team knowledge, attitudes, and emerging guidance around naloxone and patient overdose across the implementation of the pharmacist-integrated treatment model.
Evaluate naloxone co-prescribing to patients receiving medication treatment for opioid use disorder, analyzing associations with patient demographics, provider type, insurance, and drug test results.
The project seeks to facilitate greater access to naloxone and evidence-based opioid use disorder treatment through this pharmacist-integrated primary care model. The award period runs from Sep 25, 2024 to May 31, 2026.